Euphrates Vascular
Euphrates Vascular, a St. Louis-based company, innovates magnet-based medical devices for faster vascular disease treatment.
Founded
2018Euphrates Vascular, a St. Louis-based company, innovates magnet-based medical devices for faster vascular disease treatment.
Euphrates Vascular, based in St. Louis, was founded through the merger of Pulse Therapeutics and ICHOR Vascular. The company's core mission is to revolutionize the treatment of vascular diseases using advanced magnet-based technology. Their flagship product, the Pulse NanoMEDâ„¢ System, is a nanoscale interventional device designed to diagnose and treat complex vascular occlusions that are otherwise unreachable with traditional methods. Euphrates Vascular aims to significantly improve patient outcomes for conditions like stroke by accelerating the delivery of clot-busting drugs.
Notable affiliated individuals include the founders and key medical advisors from both Pulse Therapeutics and ICHOR Vascular, who bring extensive expertise in vascular health and medical device innovation. The company has attracted significant investment from healthcare-focused venture capital firms. Key achievements include the development and patenting of their Magnetically-Enhanced Diffusion system, which has shown promising results in preclinical trials. Euphrates Vascular's impact lies in its potential to transform vascular disease treatment, offering faster and more effective solutions for life-threatening conditions.
Companies similar to Euphrates Vascular include Rapidpulse, Traverse Vascular, NeuRx Medical and Pulsar Vascular.
Euphrates Vascular was founded in 2018.
Euphrates Vascular's headquarters is located in St. Louis, MO, US.
Euphrates Vascular's most recent funding round was for $9.1M (USD) in June 2021.
As of Jun 1, 2021, Euphrates Vascular has raised a total of $9.7M (USD).
Euphrates Vascular has 17 employees as of Feb 5, 2024.
NeuRx Medical
neurxmed.com
